Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
RAGE-ligand axis: A new biomarker in multiple sclerosis, time for multicentre validation study!
Critical Appraisal of Evidence for Improving Gait Speed in People with Multiple Sclerosis: Dalfampridine Versus Gait Training.
Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons.
Matrix metalloproteinases in the brain and blood-brain barrier: versatile breakers and makers.
Reproducibility measurement of glutathione, GABA, and glutamate: Towards in vivo neurochemical profiling of multiple sclerosis with MR spectroscopy at 7T.
Current and emerging treatment of multiple sclerosis.
Safety and effectiveness assessment of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: A meta-analysis.
Imaging of noninfectious inflammatory disorders of the spinal cord.
Epigenetic regulation of Kcna3-encoding Kv1.3 potassium channel by cereblon contributes to regulation of CD4+ T-cell activation.
The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?
Symptom Co-occurrences Associated with Smoking in Individuals with Relapsing-Remitting Multiple Sclerosis.
Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders.
Merging Transport Data for Choroid Plexus with Blood-Brain Barrier to Model CNS Homeostasis and Diseases More Effectively.
Delayed iron deposit and atrophy of the putamen in a case with osmotic demyelination syndrome.
Angiotensin-(1-7) Protects from Brain Damage Induced by Shiga Toxin 2-Producing Enterohemorrhagic Escherichia Coli.
Response on Paraparetic Guillain-Barré syndrome: non-demyelinating reversible conduction failure restricted to the lower limbs.
Astrocyte Dysfunction in Developmental Neurometabolic Diseases.
The Brain Proteome of the Ubiquitin Ligase Peli1 Knock-Out Mouse during Experimental Autoimmune Encephalomyelitis.
Neurological Nuance: Hodgkin Lymphoma Presenting With Guillain-Barré Syndrome.
Blockade of glutamine synthetase enhances inflammatory response in microglial cells.
WAIS-IV GAI and CPI discrepancies in multiple sclerosis and traumatic brain injury.
Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.
Neuroprotective effects of placenta-derived mesenchymal stromal cells in a rat model of experimental autoimmune encephalomyelitis.
Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
Contraceptive use among women with multiple sclerosis: a systematic review.
Pages
« first
‹ previous
…
840
841
842
843
844
845
846
847
848
…
next ›
last »